> For the complete documentation index, see [llms.txt](https://www.thiamine.wiki/llms.txt). Markdown versions of documentation pages are available by appending `.md` to page URLs; this page is available as [Markdown](https://www.thiamine.wiki/biochemistry/tpp-dependent-enzymes.md).

# tpp dependent enzymes

{% hint style="info" %}
**Section:** Complete Biochemistry → Coenzyme Pathways\
**Reading level:** Technical, with a plain-language summary\
**Last reviewed:** October 2026 · **Evidence status:** Well established (enzymology); moderate (relative sensitivity to deficiency)
{% endhint %}

## Summary

Thiamine pyrophosphate (TPP) is the coenzyme for a family of enzymes that break or make **carbon–carbon bonds next to a carbonyl group**. In humans, this family includes the gatekeepers of carbohydrate and amino acid oxidation (the **2-oxo acid dehydrogenase complexes**), the key enzyme of the non-oxidative pentose phosphate pathway (**transketolase**), and two **2-hydroxyacyl-CoA lyases** involved in fatty acid α-oxidation.

All of these enzymes share a common way of binding TPP and a common catalytic strategy based on the reactive C2 carbanion of the thiazolium ring. They differ in what happens after the substrate is attached. Their combined dependence on TPP explains why thiamine deficiency disrupts energy metabolism so broadly.

## Human TPP-dependent enzymes

| Enzyme                                                            | Gene(s)                                      | EC       | Location              | Reaction                                                            | Pathway                                                                         | Inherited disorder                                                     |
| ----------------------------------------------------------------- | -------------------------------------------- | -------- | --------------------- | ------------------------------------------------------------------- | ------------------------------------------------------------------------------- | ---------------------------------------------------------------------- |
| **Pyruvate dehydrogenase (E1 of PDHc)**                           | *PDHA1* (X-linked), *PDHA2* (testis), *PDHB* | 1.2.4.1  | Mitochondria          | Pyruvate → acetyl-CoA + CO₂ (with E2, E3)                           | Glucose oxidation                                                               | PDH deficiency (most often *PDHA1*); some variants thiamine-responsive |
| **2-Oxoglutarate (α-ketoglutarate) dehydrogenase (E1o of OGDHc)** | *OGDH*; *OGDHL* (brain-enriched isoform)     | 1.2.4.2  | Mitochondria          | 2-Oxoglutarate → succinyl-CoA + CO₂                                 | Krebs cycle                                                                     | OGDH deficiency (rare)                                                 |
| **Branched-chain α-ketoacid dehydrogenase (E1 of BCKDHc)**        | *BCKDHA*, *BCKDHB*                           | 1.2.4.4  | Mitochondria          | Branched-chain keto acids → branched acyl-CoAs + CO₂                | Leucine, isoleucine, valine catabolism                                          | Maple syrup urine disease (MSUD); some variants thiamine-responsive    |
| **2-Oxoadipate dehydrogenase (E1a)**                              | *DHTKD1*                                     | —        | Mitochondria          | 2-Oxoadipate → glutaryl-CoA + CO₂                                   | Lysine, hydroxylysine and tryptophan catabolism                                 | 2-Aminoadipic and 2-oxoadipic aciduria; Charcot-Marie-Tooth type 2Q    |
| **Transketolase**                                                 | *TKT*                                        | 2.2.1.1  | Cytosol               | Transfer of a two-carbon unit from a ketose to an aldose            | Non-oxidative pentose phosphate pathway                                         | Transketolase deficiency                                               |
| **Transketolase-like proteins**                                   | *TKTL1*, *TKTL2*                             | —        | Cytosol               | Catalytic activity disputed                                         | —                                                                               | —                                                                      |
| **2-Hydroxyacyl-CoA lyase 1**                                     | *HACL1*                                      | 4.1.2.63 | Peroxisomes           | Cleaves 2-hydroxyacyl-CoAs into formyl-CoA and a shortened aldehyde | α-Oxidation of 3-methyl-branched (e.g. phytanic acid) and 2-hydroxy fatty acids | None clearly established                                               |
| **2-Hydroxyacyl-CoA lyase 2**                                     | *ILVBL* (HACL2)                              | —        | Endoplasmic reticulum | Cleavage of 2-hydroxyacyl-CoAs                                      | α-Oxidation of 2-hydroxy fatty acids, including those from phytosphingosine     | None established                                                       |

Details of the dehydrogenase complexes are in [Oxidative Decarboxylation](broken://pages/aff327c1d64ad1abd2c61500f4b7cb2993cb7830). Transketolase is covered in [Pentose Phosphate Pathway](broken://pages/63cc26a45948f6188857defdc77e37bfecabe456).

## Shared architecture

* **Diphosphate-binding motif:** all TPP enzymes contain a conserved **GDG(X)₂₄–₂₇NN** sequence that binds the diphosphate via a divalent metal ion (Mg²⁺ or Ca²⁺).
* **Two-domain binding site:** TPP binds between a **PP domain** (holding the diphosphate) and a **Pyr domain** (holding the aminopyrimidine). These domains usually come from different subunits, so the active site lies at a subunit interface.
* **Quaternary structure:** E1 components of PDH and BCKDH are α₂β₂ heterotetramers. E1o of OGDH and transketolase are homodimers. Each has two active sites.
* **V conformation:** in all of them, TPP is held in the V conformation, which places the 4′-amino nitrogen close to C2 (see [Thiamine Structure](broken://pages/e97e22d3de70d018c7c19aa407e5feb03d96c2a0)).
* **Evolution:** the PP and Pyr domains are thought to derive from common ancestral domains that have been shuffled and rearranged across the family.

## The common catalytic cycle

{% stepper %}
{% step %}

### Activation

A conserved glutamate protonates N1′ of the aminopyrimidine. This favours the imino tautomer, whose N4′ removes the proton from C2 of the thiazolium ring, creating the reactive **ylide**.
{% endstep %}

{% step %}

### Substrate attack

The C2 carbanion attacks the carbonyl carbon of the substrate (for example, pyruvate), forming a **covalent adduct** (for pyruvate, 2-lactyl-TPP).
{% endstep %}

{% step %}

### Bond cleavage

The adduct loses CO₂ (in decarboxylating enzymes) or splits a carbon–carbon bond (in transketolase). This leaves a resonance-stabilized **enamine–carbanion** intermediate, often called the Breslow intermediate. The thiazolium ring acts as an "electron sink".
{% endstep %}

{% step %}

### Fate of the intermediate

What happens next defines the enzyme:

* **Oxidation** and transfer to lipoamide (2-oxo acid dehydrogenase E1 components);
* **Addition to an aldose acceptor** (transketolase);
* **Protonation and release** of an aldehyde (decarboxylases in microbes and plants; HACL1 and HACL2).
  {% endstep %}

{% step %}

### Release and regeneration

The product leaves and the ylide is regenerated for the next cycle.
{% endstep %}
{% endstepper %}

## Regulation

| Enzyme            | Main regulatory mechanisms                                                                                                                                                                                                                                                                                            |
| ----------------- | --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- |
| **PDH complex**   | Phosphorylation of E1α at three serine sites by pyruvate dehydrogenase kinases (PDK1–4) **inactivates** it; dephosphorylation by PDH phosphatases (PDP1, PDP2) reactivates it. Acetyl-CoA and NADH inhibit. TPP binding slows phosphorylation. The PDK inhibitor dichloroacetate has been studied in lactic acidosis. |
| **BCKDH complex** | Inactivated by BCKDH kinase (BCKDK) and activated by the phosphatase PPM1K. The keto acid of leucine inhibits BCKDK, linking substrate supply to activity.                                                                                                                                                            |
| **OGDH complex**  | Activated by Ca²⁺; inhibited by NADH, succinyl-CoA and high ATP/ADP. Sensitive to oxidative inactivation.                                                                                                                                                                                                             |
| **Transketolase** | Largely controlled by substrate availability; expression varies with tissue and metabolic state.                                                                                                                                                                                                                      |

## Sensitivity to thiamine deficiency

TPP-dependent enzymes do not lose activity equally when thiamine is short.

* **α-Ketoglutarate dehydrogenase** appears particularly sensitive in the brain. Reduced activity has been found in thiamine-deficient animal brains before visible damage, and in brains of people with Wernicke-Korsakoff syndrome.
* **Transketolase** activity falls early and can be measured in red blood cells, which is the basis of the erythrocyte transketolase test.
* **Pyruvate dehydrogenase** activity also falls, contributing to lactate accumulation.
* Prolonged deficiency can reduce the amount of **apoenzyme** (enzyme protein), not just its saturation with TPP. Some enzymes may then recover only slowly after thiamine is restored.

Reduced activities of thiamine-dependent enzymes have also been reported in brain and peripheral tissues of people with Alzheimer's disease. Whether this is a cause or a consequence of the disease remains unresolved.

## Thiamine-responsive enzyme disorders

Some inherited defects in TPP-dependent enzymes improve with high-dose thiamine.

* **Thiamine-responsive PDH deficiency:** certain *PDHA1* mutations in or near the TPP-binding region reduce the enzyme's affinity for TPP. High concentrations of thiamine can partly restore activity.
* **Thiamine-responsive MSUD:** a subset of patients with variant MSUD show reduced branched-chain keto acids on thiamine. Responsiveness has been associated with particular genotypes, notably in the E2 subunit gene (*DBT*), but the mechanism is not fully understood.

{% hint style="warning" %}
**Name clash:** the gene *DBT* (dihydrolipoamide branched-chain transacylase, the E2 subunit of BCKDH) is unrelated to the thiamine derivative dibenzoylthiamine, also abbreviated DBT.
{% endhint %}

These conditions are rare, and responsiveness must be established individually under specialist care. They are an important proof of principle that **pharmacological thiamine concentrations can compensate for reduced coenzyme binding**.

## TPP enzymes in other organisms

Many important TPP enzymes are absent from humans but matter for food science, agriculture, microbiology and drug development.

| Enzyme                                                | Organisms                                                        | Role                                              | Wider significance                                  |
| ----------------------------------------------------- | ---------------------------------------------------------------- | ------------------------------------------------- | --------------------------------------------------- |
| **Pyruvate decarboxylase**                            | Yeast, plants, some bacteria                                     | Pyruvate → acetaldehyde + CO₂                     | Alcoholic fermentation                              |
| **Acetohydroxyacid synthase (acetolactate synthase)** | Plants, bacteria, fungi                                          | First step of branched-chain amino acid synthesis | Target of sulfonylurea and imidazolinone herbicides |
| **1-Deoxy-D-xylulose 5-phosphate synthase**           | Bacteria, plants, malaria parasites                              | First step of the MEP isoprenoid pathway          | Antibacterial and antimalarial drug target          |
| **Pyruvate:ferredoxin oxidoreductase**                | Anaerobic bacteria and parasites (e.g. *Giardia*, *Trichomonas*) | Oxidative decarboxylation of pyruvate             | Involved in the action of some antiparasitic drugs  |
| **Phosphoketolase**                                   | Bifidobacteria and other bacteria                                | Sugar phosphate cleavage                          | Key to bifidobacterial metabolism                   |
| **Oxalyl-CoA decarboxylase**                          | *Oxalobacter formigenes* and others                              | Oxalate degradation                               | Gut oxalate handling                                |
| **Indolepyruvate decarboxylase**                      | Plant-associated bacteria                                        | Auxin (plant hormone) synthesis                   | Plant–microbe interactions                          |
| **MenD**                                              | Bacteria                                                         | Menaquinone (vitamin K₂) synthesis                | Antibacterial target research                       |

## Evidence quality

| Claim type                                            | Strength                                                         |
| ----------------------------------------------------- | ---------------------------------------------------------------- |
| Identity, location and reactions of human TPP enzymes | **Strong**                                                       |
| Shared structural motif and catalytic mechanism       | **Strong**                                                       |
| HACL2 as a TPP-dependent ER enzyme                    | **Moderate**: established more recently                          |
| TKTL1 catalytic activity                              | **Disputed**                                                     |
| Relative sensitivity of enzymes to deficiency         | **Moderate**: mainly animal studies and post-mortem human tissue |
| Thiamine responsiveness of PDH and MSUD variants      | **Moderate**: case reports and small series                      |

## Open questions

* Whether TKTL1 and TKTL2 have meaningful catalytic activity in human cells.
* Why α-ketoglutarate dehydrogenase is especially vulnerable in the brain.
* How quickly apoenzyme levels recover after correction of deficiency, and whether this explains slow clinical recovery.

## Related pages

* [TPP Synthesis](broken://pages/952746c8c01357a3499328e00a07994a73144702)
* [Oxidative Decarboxylation](broken://pages/aff327c1d64ad1abd2c61500f4b7cb2993cb7830)
* [Pentose Phosphate Pathway](broken://pages/63cc26a45948f6188857defdc77e37bfecabe456)
* [Ketoacid Metabolism](broken://pages/8854c82e2c5b69bab22dce371bbcd188a3d75c33)
* [Thiamine Structure](broken://pages/e97e22d3de70d018c7c19aa407e5feb03d96c2a0)

## References

1. Hawkins CF, Borges A, Perham RN. A common structural motif in thiamin pyrophosphate-binding enzymes. *FEBS Letters*. 1989;255(1):77–82.
2. Duggleby RG. Domain relationships in thiamine diphosphate-dependent enzymes. *Accounts of Chemical Research*. 2006;39(8):550–557.
3. Jordan F. Current mechanistic understanding of thiamin diphosphate-dependent enzymatic reactions. *Natural Product Reports*. 2003;20(2):184–201.
4. Patel MS, Nemeria NS, Furey W, Jordan F. The pyruvate dehydrogenase complexes: structure-based function and regulation. *Journal of Biological Chemistry*. 2014;289(24):16615–16623.
5. Foulon V, et al. Purification, molecular cloning, and expression of 2-hydroxyphytanoyl-CoA lyase, a peroxisomal thiamine pyrophosphate-dependent enzyme that catalyzes the carbon–carbon bond cleavage during α-oxidation of 3-methyl-branched fatty acids. *PNAS*. 1999;96(18):10039–10044.
6. Kitamura T, Seki N, Kihara A. Phytosphingosine degradation pathway includes fatty acid α-oxidation reactions in the endoplasmic reticulum. *PNAS*. 2017;114(13):E2616–E2623.
7. Danhauser K, et al. *DHTKD1* mutations cause 2-aminoadipic and 2-oxoadipic aciduria. *American Journal of Human Genetics*. 2012;91(6):1082–1087.
8. Xu WY, et al. A nonsense mutation in *DHTKD1* causes Charcot-Marie-Tooth disease type 2 in a large Chinese pedigree. *American Journal of Human Genetics*. 2012;91(6):1088–1094.
9. Boyle L, et al. Mutations in *TKT* are the cause of a syndrome including short stature, developmental delay, and congenital heart defects. *American Journal of Human Genetics*. 2016;98(6):1235–1242.
10. Naito E, et al. Thiamine-responsive pyruvate dehydrogenase deficiency in two patients caused by a point mutation (F205L and L216F) within the thiamine pyrophosphate binding region. *Biochimica et Biophysica Acta*. 2002;1588(1):79–84.
11. Chuang DT, Chuang JL, Wynn RM. Lessons from genetic disorders of branched-chain amino acid metabolism. *Journal of Nutrition*. 2006;136(1 Suppl):243S–249S.
12. Butterworth RF, Kril JJ, Harper CG. Thiamine-dependent enzyme changes in the brains of alcoholics: relationship to the Wernicke-Korsakoff syndrome. *Alcoholism: Clinical and Experimental Research*. 1993;17(5):1084–1088.
13. Gibson GE, et al. Reduced activities of thiamine-dependent enzymes in the brains and peripheral tissues of patients with Alzheimer's disease. *Archives of Neurology*. 1988;45(8):836–840.

{% hint style="info" %}
**Editorial note:** This page describes mechanisms and published evidence. It is not medical advice and does not recommend doses. Suggest corrections or new sources via the feedback link.
{% endhint %}
